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ABSTRACT
Comparative effectiveness research includes cohort studies and registries of interventions.When investigators design such studies, how important is
it to follow patients from the day they initiated treatment with the study interventions? Our article considers this question and related issues to start a
dialogue on the value of the incident user design in comparative effectiveness research. By incident user design, we mean a study that sets the
cohort’s inception date according to patients’ new use of an intervention. In contrast, most epidemiologic studies enroll patients who were currently
or recently using an intervention when follow-up began. We take the incident user design as a reasonable default strategy because it reduces biases
that can impact non-randomized studies, especially when investigators use healthcare databases. We review case studies where investigators have
explored the consequences of designing a cohort study by restricting to incident users, but most of the discussion has been informed by expert
opinion, not by systematic evidence. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
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INTRODUCTION
Comparative effectiveness research includes cohort
studies and registries of interventions. How important
is it to follow patients from the day they initiated
treatment with the study interventions? How well can
non-randomized studies approximate randomized
controlled trials if they follow continuing or prevalent
users? What trade-offs do investigators face when
deciding where their study will fall on the continuum
from restricting cohort enrollment to patients who are
naive to the entire class of an intervention (most
restrictive design) to expanding enrollment to patients
regardless of their past use?
Our article considers the questions outlined earlier
and related issues to start a dialogue on the value of
incident user designs in comparative effectiveness
research. We take the incident user design as a
reasonable default strategy because it reduces biases,
especially when investigators use secondary data
sources, such as healthcare databases. Although the
incident user design is preferable on theoretical
grounds, there may be exceptions where that eligibility
criterion does not matter and a less restrictive study
design may provide a valid answer that is more timely,
more affordable, and more applicable to routine care.
We review case studies where investigators have
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explored the consequences of designing a cohort study by
restricting to incident users, but most of the discussion
has been informed by expert opinion, not by systematic
evidence. Because we only reviewed published literature,
human subjects’ approval was not required.
The objectives of this article were to consider the
incident user design as a default or ﬁrst-line study
design for comparative effectiveness research and to
provide guidance with discussion on the advantages
and limitations of the approach. We organized the
article as follows: (i) issues that motivate the incident
user design; and (ii) deﬁnition of incident users in
retrospective studies: trade-offs for internal validity
and applicability (with further discussion on internal
validity, trade-offs, and related design and analysis
choices in the Supporting Information). We end with
a brief set of recommendations for reporting.
ISSUES THAT MOTIVATE THE INCIDENT USER
DESIGN
Investigators struggle to design non-randomized studies
that obtain ﬁndings as credible as those from random-
ized controlled trials. To achieve that credibility, they
restrict the question, the design, and the analysis.1–3
However, investigators designing non-randomized
studies typically cannot achieve the additional
credibility attained through blinding or masking
patients and providers to the interventions.4
Without the incident user design, investigators may
struggle to replicate the eligibility criteria of a random-
ized controlled trial. For example, a patient who appears
eligible today as a current user of an intervention may
have been too young to be eligible at the time he or
she started the intervention years earlier. It could also
be that his or her laboratory and blood pressure ﬁndings
may have been modiﬁed by years of intervention so that
he or she now appears ineligible, although he or she
would have met criteria at the time he or she started
the intervention. Consequently, alternatives to the
incident user design can generate uncertainty about the
population’s eligibility and complicate comparisons
across studies.
Sometimes, the ﬁndings from non-randomized
studies of comparative effectiveness disagree with
the ﬁndings from randomized controlled trials.
Discrepancies between the cardiovascular ﬁndings
from the Women’s Health Initiative (WHI) clinical trial
and its cohort study of hormone therapy—as well as other
studies on the topic—may be the most discussed
example.5–8 Ray suggested that the discrepancy may be
explained, in part, by restricting non-randomized studies
to new (or incident) users of hormone therapy because
the incident user design can reduce biases that occur
when comparisons include patients who were already
using the drug at the start of the study.5
Yet, other investigators have approximated the ﬁnd-
ings from randomized controlled trials by comparing
current users of drug therapy and ignoring the duration
of drug use. For example, Psaty and colleagues
reported that current users of angiotensin-converting
enzyme inhibitors and current users of diuretics
experienced a similar rate of myocardial infarction:
Their case–control study ﬁndings (for that comparison
and outcome) agreed closely with similar head-to-head
comparisons in theAntihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT).9,10
Ray and colleagues found that the excess rate of coronary
heart disease events among patients using COX-2 selec-
tive non-steroidal anti-inﬂammatory drugs (NSAIDs)
was consistent for current users and the subgroup of inci-
dent users—a rare comparison of strategies for deﬁning
cohorts within a cohort study.11 Given the inconsistency
in these examples, what is the theoretical motivation to
prefer the incident user design over other choices that
enroll continuing or prevalent users? Below, we consider
two theoretical motivations. Although it is beyond the
scope of this article, there are additional theoretical
motivations for the incident user design including the
clear articulation of a causal question about the beneﬁts
or harms of starting interventions; in contrast, the
counterfactual may be harder to articulate for studies that
enroll continuing or prevalent users.
Avoiding adjustment of intermediate covariables
One reason to prefer the incident user design is that it
avoids the problem of adjusting for characteristics that
may be in the causal pathway.5 For example, in the
case–control study noted earlier, Psaty and colleagues
went to exceptional effort to obtain patients’ pretreat-
ment blood pressure values, which were documented
in paper charts at the health maintenance organization
(HMO) an average of 11 years before the date that
determined current drug use.9 Even with that effort,
pretreatment blood pressure values were missing in
one third of patients who started treatment before
joining the HMO. Had Psaty and colleagues adjusted
for patients’ most recent blood pressure values, they
would have biased the comparisons between classes
of antihypertensive drugs because the most recent
blood pressure value is in the causal path between
treatment and myocardial infarction and shares
common causes with myocardial infarction. Because
most non-randomized studies lack detailed historical
data on pretreatment characteristics, it is often more
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credible to restrict the design to incident users—for
whom such pretreatment characteristics can be collected
more completely and reliably.
A fair representation of early and late events
The second reason to prefer the incident user design is
that it captures all events that occurred after the start of
therapy.5,12,13 Molride and Abenhaim explained that
some patients are susceptible to harm from a drug,
and those events may occur earlier in the course of
therapy. Once these susceptible patients have suffered
events early in the course of therapy, only less suscep-
tible patients remain. Mixing incident and prevalent
users may obscure excess harm because the effect
measure is weighted toward prevalent users who
provide the majority of person-time and were less
susceptible to the harm.13,14 Similar concerns apply
to any outcome, including beneﬁts, when the popula-
tion is required to survive during the intervention.
Guess described a related idea by noting that the
hazard ratio for harm changed over time since the start
of drug use.15 Such changes in effect size as a function
of the duration of drug use may result from shifts in
cohort composition—as described earlier— or biologic
effects or both. Similarly, an intervention’s beneﬁts
may require an induction period of months or years to
reduce clinical event rates: Newly diagnosed patients
with diabetes who started intensive therapy for glucose
control took up to 10 years to achieve the clinical
beneﬁts in the United Kingdom Prospective Diabetes
Study.16 When Prentice and colleagues considered
patients’ duration of hormone therapy—before the start
of the study—in the WHI cohort study, their ﬁndings
approximated more closely the ﬁndings from theWHI’s
controlled trial—at least for some endpoints.6
Newly marketed drugs may have a disproportionate
share of incident users compared with drugs that were
marketed years earlier. For example, a cohort study
that was conducted shortly after the marketing of
celecoxib that compared patients currently using
celecoxib versus those currently using naproxen could
distort estimates of comparative effectiveness because
the celecoxib users would be more likely to be incident
users at higher risk of any early harms related to
NSAIDs. Restricting enrollment to incident users
enables comparisons at a comparable time in the
natural history of their treatment.
Ray traced the idea of the incident user design back
to Feinstein’s article on chronology bias, which
appeared in 1968.17 Ray’s own review of new user
design for non-randomized studies remains the most
comprehensive account of its value in reducing bias.5
McMahon and MacDonald provided an earlier and
thoughtful consideration of the new user design.12 A
task force on research practices for retrospective
databases organized by the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR)
has also addressed the incident user design and its
alternatives.14 Our article builds on their efforts by
considering how the incident user design applies
to comparative effectiveness research. We expand
on their previous discussions to consider other
interventions, such as medical devices, although
most of the examples concern medications. This
article asks that investigators consider the incident
user design as a default strategy but recognizes that
there will be exceptions where current user designs
may be preferred. This article encourages more
transparent reporting of design choices—in the
spirit of STROBE (Strengthening the Reporting of
Observational Studies in Epidemiology)—and an
appreciation of the trade-offs that those choices
may entail for validity, applicability, timeliness,
and feasibility.18
DEFINING INCIDENT USERS IN
RETROSPECTIVE STUDIES: TRADE-OFFS FOR
INTERNAL VALIDITY AND APPLICABILITY
No consensus exists for deﬁning an incident user of a
drug or other intervention using secondary data sources,
such as computerized pharmacy ﬁll records or electronic
health record prescription orders (see Supporting Infor-
mation for a discussion of related ideas as they apply to
prospective studies). Ray and colleagues deﬁned incident
use of NSAIDs as patients who had not ﬁlled those
medications in the 365 days preceding time zero.11 In
theory, the physician’s order date, or prescription,
recorded in some electronic health records, could serve
as a more meaningful time zero for approximating a
cohort study analogue of the intention-to-treat analysis
used in randomized controlled trials.19 For example,
some physicians may dispense product samples along
with a prescription; if the patient tolerates the sample,
then he or she may ﬁll the prescription, which would
appear later as a pharmacy claim. Consequently, the
prescription date could reﬂect the start of therapy more
accurately.20 However, some patients will not ﬁll the
prescription, sometimes called primary non-adherence,
which would attenuate the comparative effect.
Recurrent use
Because some health plans will allow patients to ﬁll a
180-day supply of medication, submitted as a single
pharmacy claim, briefer deﬁnitions may misclassify
patients who actually used their medication during
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the baseline period. For example, a patient may have
ﬁlled his prescription 200 days before the date selected
to deﬁne incident use. If the study used 180 days to
deﬁne incident users, he or she would appear to be
an incident user but would have been taking medica-
tion during the months when baseline characteristics
were measured. The challenge is more complicated
than it may seem: Some patients take long drug
holidays and then restart their medication.21 Others
adhere so poorly—say, every other day—that a
prescription intended as a 90-day supply can persist for
180 days. Recognizing the range of possibilities brings
a sense of humility about classifying patients as incident
users; only a proportion of apparent incident users are
truly treatment naive as of the date that investigators
assign for time zero. Some investigators may prefer a
data-driven method for identifying the number of days
that deﬁne incident use in their population by using
pharmacy databases and the waiting time distribution.22
When investigators know that a patient has used
the intervention in the past, one option is to stratify
comparative estimates so that each group has its
own baseline hazard for calculating the hazard ratio
that captures comparative effectiveness. For example,
patients with a known history of NSAID use more than
365 days before time zero could be compared with
other patients who had the same known history. If
the investigators know that medication is used episod-
ically (e.g., cycles of chemotherapy) and they wish to
capture the totality of beneﬁts and harms across those
episodes, then they should consider more complex
structural models that address time-varying drug expo-
sures and confounders; otherwise, it is preferable to
evaluate the beneﬁts and harms for the ﬁrst observed
episode only.23
Recently marketed drugs
For a recently marketed drug, deﬁning incident use as
no ﬁlls in the preceding 365 days may identify patients
for whom the ﬁrst observed prescription ﬁll in a given
database represents their ﬁrst ever use (i.e., truly
treatment naive). For older drugs, deﬁning incident
use as no ﬁlls in the preceding 365 days may identify
patients starting a new episode of therapy, but not
necessarily their ﬁrst ever use. For example, when
Ray and colleagues conducted their cohort study using
pharmacy data from 1999 through 2001, naproxen had
been marketed in the USA since 1980; consequently,
apparent incident users during 1999 through 2001
may have had past episodes of naproxen use and
survived any harms that they experienced during
earlier episodes.2,11 In contrast, apparent incident users
of the more recently marketed COX-2 selective
NSAIDs, celecoxib and rofecoxib, were more likely
to be treatment naive—at least to those products (but
not all NSAIDs). If investigators wish to analyze
recurrent episodes of therapy, it is important to adjust
standard errors for the correlation of episodes within
patients to obtain the correct conﬁdence intervals.24
Stricter deﬁnitions of incident use
Stricter deﬁnitions of incident use may improve the
internal validity of comparative effectiveness esti-
mates for the reasons outlined in the previous section.
However, those improvements in validity entail trade-
offs for applicability and precision. For example,
patients starting therapy after 365 days without
therapy may be at an earlier point in the natural history
of their illness (or may be experiencing a milder
severity) and therefore at a lower absolute risk of
clinical events than that of patients who would be
eligible according to a 180-day or 90-day wash-out
period, a term borrowed from randomized controlled
trial protocols.25 The extent of any difference in the
absolute risk probably depends on the indication and
the duration that deﬁned incident use.When Schneeweiss
and colleagues calculated the rate of suicide and suicide
attempts for all incident users of serotonin reuptake
inhibitors (SSRIs), they found that the 1-year rate was
slightly higher in incident users deﬁned by 1 year without
an antidepressant medication (6.03 per 1000 person
years; 95% CI, 5.54–6.55) than in incident users deﬁned
by 3 years without an antidepressant medication (5.18 per
1000 person years; 95% CI, 4.65–5.75).26
For comparisons of ﬁrst-line therapies, validity will
be improved by insisting that patients have not used
any therapies in the entire class or related classes
(e.g., no selective SSRIs or serotonin–norepinephrine
reuptake inhibitors). However, requiring patients to
have no use of any therapies in the entire class—versus
requiring patients to have no use of a speciﬁc product or
intervention—could reduce applicability by excluding
patients with more severe symptoms or patients at a later
stage in their natural history. Consider the problem of
comparing second-line therapies for rheumatoid
arthritis, such as the initiation of TNF alpha antagonists.
Most of these patients used other disease-modifying
antirheumatic drugs and have now switched to a
second-line therapy. In this situation, or similar scenar-
ios, stepped-up therapy correlates with progression of
the condition. Consequently, investigators should differ-
entiate between comparative effectiveness in ﬁrst-line
therapy versus comparative effectiveness in second-line
therapy.27 For second-line therapy, the cohort would be
e. s. johnson et al.4
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deﬁned by using a common ﬁrst-line therapy, say
methotrexate in the arthritis example, and the study
intervention would be the addition of or switch to a
product in the class of TNF alpha antagonists. Such a
comparison of incident second-line users would
improve the comparability of patients’ arthritis severity
and progression because they required stepped-up
therapy. However, the duration and intensity of the
ﬁrst-line therapy may be a confounder for the second-
line drug analysis.
Reduced study size as a consequence of increasing
restrictions
An incident user cohort based on the 365-day
deﬁnition may produce a less biased estimate of
comparative effectiveness, but that ﬁnding (e.g.,
the risk difference) may not apply to as many
patients with the condition. Restricting enrollment
to incident users can dramatically reduce the size
of the cohort and the precision of the comparative
effectiveness estimates. For example, when Schneeweiss
and colleagues identiﬁed elderly patients who ﬁlled statin
therapies according to a pharmacy claims database,
approximately 61000 met the deﬁnition of current use
(as of the index date), but approximately 21 000 patients
met the 365-day deﬁnition for incident use.2 Investigators
with secondary data sources may ﬁnd that deﬁnitions
requiring more than 365 days exclude another 20%
or more of patients: In US insurance plans, 20% of
members typically discontinue insurance coverage an-
nually, often switching to a new insurance plan.28
Stricter deﬁnitions of incident use may reduce the
precision of comparative effectiveness estimates to a
point where the conﬁdence intervals can no longer rule
out clinically important levels of harm or beneﬁt. In
some instances, stricter deﬁnitions of incident use
may require multicenter studies to achieve adequate
precision—especially for testing equivalence and
non-inferiority hypotheses.29
RECOMMENDATIONS FOR REPORTING
Based on our review, we propose the following recom-
mendations for reporting.
(1) Investigators should report whether they designed
the study to compare incident users of the interven-
tion or whether they enrolled patients according to
different eligibility criteria. Those eligibility criteria
and their effect on the numbers of patients should
be documented in a CONSORT-style participant
ﬂow diagram that will allow readers to assess
the applicability of the ﬁndings to their popula-
tions and settings.30
(2) Investigators should report how they deﬁned the
dates of intervention use and, for studies that
followed incident users, the time used to classify
patients as incident users along with the clinical
rationale for that time.
(3) Investigators should report whether the baseline
characteristics were measured before incident drug
use or whether those characteristics may reﬂect the
effects of the study deﬁning interventions. For
characteristics measured before incident drug use,
investigators should report the timing of those mea-
surements in relation to the start of the intervention.
(4) Investigators should conduct sensitivity analyses
with varying deﬁnitions of incident use to
illustrate the stability of ﬁndings with respect to
validity and precision.
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KEY POINTS
• We take the incident user design as a reasonable
default strategy because it reduces confounding
and adjustment for intermediate characteristics
in the causal path.
• The incident user design results in more effective
propensity scores because the baseline character-
istics that contribute to the score predict incident
use of interventions.
• The incident user design allows investigators to
identify all of the outcomes that may be related
to the intervention; prevalent user designs may
miss some early events.
• Although the incident user design offers many
advantages, the most obvious trade-off is a loss of
precision in estimates of comparative effectiveness;
a multisite study may be required to obtain a
sufﬁcient number of incident users.
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